ArticlePloS one2025
Risk factors for multidrug-resistant and carbapenem-resistant Klebsiella pneumoniae bloodstream infections in Shanghai: A five-year retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for carbapenem-resistantFrontiers in public health · 2026Pooled it
- Clinical outcomes and mortality in carbapenem-resistant versus susceptible Klebsiella pneumoniae bloodstream infections in intensive care units.BMC infectious diseases · 2026Article
- Development and Validation of a Nomogram for Predicting Mortality in Patients with Multidrug-Resistant Bacteria Infection: A Retrospective Cohort Study in China.International journal of general medicine · 2026Article
- Genomic Epidemiology and Plasmid-Mediated Dissemination of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Clinical and molecular characteristics, antibiotic susceptibility, risk factors and predictors of mortality in carbapenem-resistant klebsiella pneumoniae bloodstream infections in Southern Sichuan, China: a 5-year multicenter study.Frontiers in cellular and infection microbiology · 2026Article
- Clinical Characteristics and Independent Risk Factors for Multidrug-ResistantInfection and drug resistance · 2025Article
- FromFrontiers in medicine · 2025Article
- Standardized pre-bronchoscopy mechanical power and KPC resistance as predictors of mortality in ventilated ICU patients: a retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant Klebsiella pneumoniae (MDRKP) and carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections (BSIs) account for significant mortality and healthcare costs.
objectivesTo investigate risk factors for MDRKP and CRKP BSIs.
methodsA retrospective analysis of inpatients with Klebsiella pneumoniae bloodstream infections (KP BSIs) was conducted in a tertiary care hospital in Shanghai from 01/01/2018-31/12/2022. Temporal distribution of mortality and department distribution of KP BSIs were assessed. A generalized linear model was used to determine risk factors for MDRKP and CRKP BSIs.
resultsA total of 379 inpatients with KP BSIs were included. The proportion of death for KP BSIs, MDRKP BSIs and CRKP BSIs gradually decreased since 2020. Majority of both MDRKP and CRKP BSIs patients were from Intensive Care Unit (ICU), burn unit, hematology and pancreatic surgery. Genitourinary disorders, invasive ventilator, history of antibiotic use, and carbapenem use were independently associated with MDRKP BSIs. Respiratory disease, gastric tubes, carbapenem use and its quantity were independently associated with CRKP BSIs.
conclusionsICU, burn unit, hematology and pancreatic surgery are common departments for MDRKP and CRKP BSIs. Genitourinary disorders, respiratory disorders, invasive ventilator, gastric tubes and antibiotic use (carbapenems in particular) within 90 days prior to onset of BSIs are independently associated with MDRKP and CRKP BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.